Elevated Levels of β-Endorphin in Temporomandibular Joint Synovial Lavage Fluid of Patients with Closed Lock

Aims: To investigate the presence of endogenous β-endorphin, an opioid, in the synovial lavage fluid of the temporomandibular joint (TMJ), and to compare the concentration of β-endorphin in patients with closed lock with that in symptom-free subjects. Methods: Thirty-eight patients (38 joints) with closed lock diag-nosed on the basis of the results of clinical examination and mag-netic resonance imaging (MRI) and 11 healthy volunteers (19 joints) were examined. Samples of lavage fluid were obtained prior to arthrocentesis by washing the joint with saline. Samples were assayed for β-endorphin by an enzyme immunoassay, and concen-trations of protein were measured by a bicinchoninic acid assay. Subjective pain was assessed by patients using a visual analog scale. Bone changes in the condyle were assessed by MRI, and syn-ovitis was assessed on the basis of arthroscopic findings. Results: β-endorphin was present in the synovial fluid of the TMJ, and the concentration was significantly higher in patients with closed lock of the TMJ compared to symptom-free volunteers. The β-endor-phin levels were not, however, significantly correlated with clinical parameters in the patients. Conclusion: The study results support recent findings that some opioids and their receptors exist not only within the central nervous system but also in the TMJ region, and that opioid concentrations are higher in patients with pain and dysfunction of the TMJ.

arthrocentesis; β-endorphin; synovial fluid; temporomandibular joint

1. Milam SB, Schmitz JP. Molecular biology of temporo-mandibular joint disorders: Proposed mechanisms of disease. J Oral Maxillofac Surg 1995;53:1448–1454.

2. Milam SB, Zardeneta G, Schmitz JP. Oxidative stress and degenerative temporomandibular joint disease: A proposed hypothesis. J Oral Maxillofac Surg 1998;56: 214–223.

3. Kopp S. Neuroendocrine, immune, and local responses related to temporomandibular disorders. J Orofac Pain 2001;15:9–28.

4. Hayashi K, Sugisaiki M, Ota S, Tanabe H. µ-Opioid receptor mRNA expression and immunohistochemical localization in the rat temporomandibular joint. Peptides 2002;23:889–893.

5. Bakke M, Hu JW, Sessle BJ. Morphine application to peripheral tissues modulates nociceptive jaw reflex. Neuroreport 1998;9:3315–3319.

6. Denko CW, Aponte J, Gabriel P, Petricevic M. β-Endorphin, immunological and biochemical changes in synovial fluid in rheumatic disorders. Clin Rheumatol 1986;5: 25–32.

7. Suzuki N, Yoshino S, Nakamura H. A study of opioid peptides in synovial fluid and synovial tissue in patients with rheumatoid arthritis [in Japanese]. Arerugi 1992;41: 615–620.

8. Bender T, Barna I, Geher P. Synovial immunoreactive β-endorphin levels in rheumatoid arthritis and osteoarthritis. Clin Exp Rheumatol 1999;17:630.

9. Yoshino S, Koiwa M, Shiga H, Nakamura H, Higaki M, Miyasaka N. Detection of opioid peptides in synovial tissues of patients with rheumatoid arthritis. J Rheumatol 1992;19:660–661.

10. Stein C, Hassan AH, Lehrberger K, Giefing J, Yassouridis A. Local analgesic effect of endogenous opioid peptides. Lancet 1993;342:321–324.

11. Przewlocki R, Hassan AH, Lason W, Epplen C, Herz A, Stain C. Gene expression and localization of opioid peptides in immune cells of inflamed tissue: Functional role in antinociception. Neuroscience 1992;48:491–500.

12. Takeba Y, Suzuki N, Kaneko A, Asai T, Sakane T. Endorphin and enkephalin ameliorate excessive synovial cell functions in patients with rheumatoid arthritis. J Rheumatol 2001;28:2176–2183.

13. Soderlund A, Boreus LO, Westman L, Engstrom B, Valentin A, Ekblom A. A comparison of 50, 100 and 200 mg of intra-articular pethidine during knee joint surgery, a controlled study with evidence for local demethylation to norpethidine. Pain 1999;80:229–238.

14. Stein A, Yassouridis A, Szopko C, Helmke K, Stein C. Intraarticular morphine versus dexamethasone in chronic arthritis. Pain 1999;83:525–532.

15. Bryant CJ, Harrison SD, Hopper C, Harris M. Use of intra-articular morphine for postoperative analgesia following TMJ arthroscopy. Br J Oral Maxillofac Surg 1999; 37:391–396.

16. Furst IM, Kryshtalskyj B, Weinberg S. The use of intra-articular opioids and bupivacaine for analgesia following temporomandibular joint arthroscopy: A prospective, randomized trial. J Oral Maxillofac Surg 2001;59:979–983.

17. List T, Tegelberg Å, Haraldson T, Isacsson G. Intra-articular morphine as analgesic in temporomandibular joint arthralgia/osteoarthritis. Pain 2001;94:275–282.

18. Cai BBY, Cairns BE, Sessle BJ, Hu JW. Sex-related suppression of reflex jaw muscle activity by peripheral morphine but not GABA. Neuroreport 2001;12:3457–3460.

19. Bragdon EE, Light KC, Costello NL, et al. Group differences in pain modulation: Pain-free women compared to pain-free men and to women with TMD. Pain 2002;96: 227–237.

20. Kubota E, Imamura H, Kubota T, Shibata T, Murakami K. Interleukin 1 beta and stromelysin (MMP3) activity of synovial fluid as possible markers of osteoarthritis in the temporomandibular joint. J Oral Maxillofac Surg 1997; 55:20–27.

21. Mabuchi A, Yura S, Ooi K, et al. Incidence of disc deformity and bone changes in patients with anterior disc displacement without reduction of the temporomandibular joint: Comparison among different age groups. J Jpn Soc TMJ 2003;15:13–17.

22. Yu X-M, Sessle BJ, Vernon H, Hu JW. Administration of opiate antagonist naloxone induces recurrence of increased jaw muscle activities related to inflammatory irritant application to rat temporomandibular joint region. J Neurophysiol 1994;72:1430–1433.

23. Stein C. The control of pain in peripheral tissue by opi-oids. N Engl J Med 1995;332:1685–1690.

24. Okeson JP (ed). Orofacial Pain, Guidelines for Assessment, Diagnosis, and Management. Chicago: Quintes-sence, 1996:131.

25. Murakami KI, Shibata T, Kubota E, Maeda H. Intra-articular levels of prostaglandin E2, hyaluronic acid, and chondroitin-4 and -6 sulfates in the temporomandibular joint synovial fluid of patients with internal derangement. J Oral Maxillofac Surg 1998;56:199–203.

26. Alstergren P, Kopp S. Prostaglandin E2 in temporo-mandibular joint synovial fluid and its relation to pain and inflammatory disorders. J Oral Maxillofac Surg 2000; 58:180–186.

27. Kajii T, Suzuki K, Yoshikawa M, Imai T, Matsumoto A, Nakamura S. Long-term effects of prostaglandin E2 on the mineralization of a clonal osteoblastic cell line (MC3T3-E1). Arch Oral Biol 1999;44:233–241.

28. Kest B, Sarton E, Dahan A. Gender differences in opioidmediated analgesia: Animal and human studies. Anesthe-siology 2000;93:539–547.

29. Bereiter DA, Bereiter DF, Ramos M. Vagotomy prevents morphine-induced reduction in Fos-like immunoreactivity in trigeminal spinal nucleus produced after TMJ injury in a sex-dependent manner. Pain 2002;96:205–213.